Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Narrative Review of Stem Cell-Derived Exosomes for Diabetic Nephropathy.

Stem cells international·2026
Same author

Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation.

Cancers·2026
Same author

Serum-Derived Extracellular Vesicles as Biological Indicator of Mobility Resilience in Older Adults.

Aging cell·2026
Same author

A Prospective Real-world Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin among People with Type 2 Diabetes Mellitus Who are Intolerant to Metformin (PRISM Study).

The Journal of the Association of Physicians of India·2026
Same author

Adipose Tissue-Derived Small Extracellular Vesicles in Plasma Reveal Molecular Circuitries Underlying Glucose Intolerance.

Obesity (Silver Spring, Md.)·2026
Same author

Distinct Tumor Infiltrating Immune Cell Profiles in Mice by Non-Steroidal Anti-Inflammatory Drugs (Aspirin and Naproxen) During TMPRSS2-ERG (Fusion)-Driven and Non-Fusion Driven Prostate Cancer.

Molecular carcinogenesis·2026

Related Experiment Video

Updated: Jul 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

New combination therapies with cell-cycle agents.

Gagan Deep1, Rajesh Agarwal

  • 1University of Colorado Denver, School of Pharmacy, Department of Pharmaceutical Sciences, East 4200 9th Street, Box C238, Denver, CO 80262, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|June 3, 2008
PubMed
Summary

Targeting cancer cell-cycle progression is crucial for therapy. While cell-cycle inhibitors show modest clinical efficacy, combining them with chemotherapy may improve cancer burden reduction.

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Related Experiment Videos

Last Updated: Jul 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Cancer cells exhibit deregulated cell-cycle progression, enabling unlimited replication.
  • Targeting the cell cycle is a key strategy in cancer therapy.
  • Existing cell-cycle-based agents include cyclin-dependent kinase inhibitors, Cdc25 inhibitors, checkpoint inhibitors, and mitotic inhibitors.

Purpose of the Study:

  • To review the development and clinical efficacy of cell-cycle-based agents in cancer therapy.
  • To explore the potential of combining cell-cycle inhibitors with traditional chemotherapeutic drugs.

Main Methods:

  • Review of preclinical and clinical studies on cell-cycle inhibitors.
  • Analysis of combination therapy approaches involving cell-cycle agents and chemotherapy.

Main Results:

  • Cell-cycle inhibitors have shown preclinical efficacy but modest clinical success due to side effects.
  • Combination studies suggest potential benefits in reducing cancer burden.

Conclusions:

  • Despite modest clinical efficacy of monotherapy, cell-cycle inhibitors hold promise.
  • Combining cell-cycle agents with chemotherapy presents an encouraging strategy for enhanced cancer treatment.